Rationale: AMP-activated protein kinase (AMPK) has been reported to play a protective role in atherosclerosis.
A therosclerosis, characterized by the accumulation of lipids and inflammatory cells in the large arteries, is one of the most common causes of morbidity and mortality in developed and developing countries. 1, 2 Atherosclerotic plaque rupture-induced thrombosis or obstruction of coronary artery is the most important cause for the sudden and unpredictable onset of acute coronary syndromes. 3 Vulnerable plaques have thin fibrous caps and contain reduced collagen contents. Vascular smooth muscle cells (VSMCs), which are able to form and maintain the fibrous cap and synthesize collagen, 4 play a pivotal role in enhancing plaque stability in advanced lesions. Most studies of the role of VSMC on atherosclerotic plaque stability are focused on VSMC apoptosis. 5, 6 It has been shown that apoptosis of VSMC induces features of plaque vulnerability in atherosclerosis. 7 However, recently, Shankman et al 8 reported that the contribution of VSMC to atherosclerotic plaques has been greatly underestimated, and Kruppel-like factor 4 (KLF4)-dependent transitions in SMC phenotype are critical in lesion pathogenesis. Using VSMC-specific KLF4 knockout mice, they identified that KLF4 deletion increases multiple indices of plaque stability, suggesting that therapeutic approaches aimed at reducing KLF4 may be a viable means of treating advanced atherosclerosis. But how KLF4 itself is regulated in atherosclerosis remains unclear. Over the years, pathogenic factors causing atherosclerotic plaque instability have been a subject of intensive investigation.
AMP-activated protein kinase (AMPK) is a serine/threonine kinase composed of α, β, and γ subunits. 9, 10 The α subunit, which controls catalytic activity, has 2 isoforms, α1 and α2, that are differentially expressed in various cell types. 11, 12 All 3 major cell types in the vasculature (endothelial cells, VSMC, and monocytes/macrophages) express AMPKα. The major isoform in these vasculature cells is AMPKα1, whereas AMPKα2 is the minor isoform. Despite being the minor isoform, AMPKα2 plays an important role in cardiovascular diseases. Recent studies indicate that AMPK not only functions as an intracellular energy sensor and regulator 13, 14 but also plays critical roles in the pathogenesis of several cardiovascular diseases. 15, 16 For example, genetic deletion of AMPKα2 in endothelial cells accelerates atherosclerosis by promoting NAD(P)H oxidase, reactive oxygen species (ROS), endothelial dysfunction, and endoplasmic reticulum stress. 17, 18 In addition, AMPKα2 deletion in VSMC promotes neointimal formation by enhancing VSMC migration and proliferation. 19, 20 But the contributions of VSMC-derived AMPKα2 in atherosclerosis and plaque stability remain unknown.
By using loss-of-function approach (global AMPKα2 −/− and VSMC-specific AMPKα2 −/− mice) and activation of AMPKα2 by pravastatin, we aimed to determine the effect and molecular mechanisms of AMPKα2 on atherosclerosis and atherosclerotic plaque stability. Our results indicate that AMPKα2 deletion in VSMC promotes features of atherosclerotic plaque instability via upregulating KLF4 expression. Conversely, pravastatin suppressed VSMC phenotypic switching and enhanced plaque stability via AMPKα2 activation. 
Methods Animal Diet, Feeding Schedule, and Preparation of Tissues

AMPKα2
sm−/− mice were placed on Western diet for the initial 6 weeks to establish aortic lesions. In the presence of Western diet, mice were treated with 50 mg/kg per day pravastatin for an additional 4 weeks. Saline solution was used as solvent control. Mice were euthanized, and blood was collected. Mice were then perfused via the left ventricle with 5-mL PBS followed by 10-mL 4% paraformaldehyde. Brachiocephalic arteries (BA) were carefully dissected and fixed overnight in 4% paraformaldehyde before embedding in optimum cutting temperature compound (OCT; BDH Laboratory Supplies). Details of materials and experimental procedures are in the Methods section in the Online Data Supplement.
Results
AMPKα2 Deletion Enhances Features of Atherosclerotic Plaque Instability
To examine the effects of AMPKα2 deletion on atherosclerotic plaque stability at the BA, we first analyzed the lesion sizes with oil-red-O staining. Consistent with our previous report, 17 Apo e
AMPKα2
−/− mice exhibited an elevation in atherosclerotic plaque size spanning >6 locations within the BA compared with those of Apoe −/− controls (Online Figure IA through ID) . The phenotypic characteristics of vulnerable plaques include increased intraplaque hemorrhage, 21, 22 presence of buried fibrous cap, 23, 24 presence of discontinuity in the fibrous cap, 25 increased lipid-rich necrotic core size, decreased thickness of fibrous cap, 23 decreased plaque collagen content, 26, 27 increased macrophage content, 28, 29 and increased matrix metallaproteases (MMPs), all of which have been widely used as indicators of plaque instability. To test whether AMPKα2 deletion influence the features of plaque stability, the aforementioned parameters were detected within the BA, a widely used artery for studying plaque stability or vulnerability in terms of an advanced atherosclerotic lesion in a mouse model. Intraplaque hemorrhage ( Figure 1A , black arrow), defined as the presence of erythrocytes within the plaque, contributes independently to plaque instability as they promote oxidative stress and cholesterol accumulation, 30 was significantly increased in Apoe Figure 1A , black arrowhead and 1C). The presence of fibrous cap discontinuity, which also called acute plaque rupture, defined as a visible breach in the cap, 32 may directly reflect plaque rupture and was found increased in Apoe
−/− mice ( Figure 1D ). Furthermore, plaque necrosis, which contributes to inflammation, thrombosis, physical stress on the fibrous cap, and plaque breakdown, 33 was analyzed, and the result showed that the necrotic core size in Apoe
−/− mice was significantly increased relative to Apoe −/− mice ( Figure 1E and 1F). Fibrous cap area, which is widely used as an indirect indicator of plaque stability, was markedly decreased in Apoe
−/− mice relative to controls, consistent with features of unstable plaques in humans ( Figure 1G and 1H) . Also, plaque collagen content, which plays an important structural role in stabilizing plaques, 34 was decreased in Apoe
−/− mice relative to control mice ( Figure 1I and 1J ). In addition, macrophage content was increased within plaques from Apoe
−/− mice relative to controls, which is also consistent with increased plaque instability ( Figure 1K and 1L) . Finally, the expression of MMP2, which is a key factor in promoting the vulnerability of an atherosclerotic plaque, was significantly increased in plaque-enriched areas of the BA in Apoe
−/− mice relative to control mice (Online Figure II) 
−/− mice relative to Apoe −/− controls (Figure 2A through 2C) . Although vimentin, which is considered a marker of synthetic VSMC, 35 was significantly increased in the Apoe
−/− mice compared with the Apoe −/− controls ( Figure 2D through 2F ). In addition, the expression of SMA-α and vimentin in the media of BA (in which the major cell type is VSMC) showed similar trend with that in the plaque area. All these results demonstrate that AMPKα2 deletion promotes contractile VSMC switching to the synthetic phenotype, which might lead to plaque instability.
AMPKα2 Deletion Upregulates KLF4 Expression in Advanced Atherosclerotic Plaque in BA
KLF4 is a transcription factor of the KLF family and regulates differentiation, proliferation, and apoptosis.
36 KLF4 is a wellknown negative transcriptional factor for VSMC contractile proteins, which is reported to be upregulated in VSMC phenotype modulation and plaque instability. 8 We reasoned that AMPKα2 deletion causes increased KLF4 resulting in VSMC phenotypic switching and plaque instability. To this end, we detected KLF4 expression in the plaques of BA from Apoe −/− and Apoe
AMPKα2
−/− mice. As shown in Figure 3A and 3B, KLF4 expression was significantly increased in both the plaque areas and media layer of the vessel (mainly VSMC) in Apoe 
Kα2
−/− mice relative to that of Apoe −/− mice. To further identify the origin of increased KLF4, immunofluorescence costaining of KLF4, SMA-α, and CD68 indicated that there was a weak costaining of KLF4 and macrophage marker CD68 (pink) in the plaque of BA in both Apoe −/− and Apoe Figure III) , suggesting that the major origin of increased KLF4 in AMPKα2 −/− mice is VSMC. These results indicate that KLF4 might be required for AMPKα2 deletion-induced VSMC phenotypic switching and plaque instability.
VSMC-Specific AMPKα2 Deletion but Not Macrophage-Specific AMPKα2 Deletion Exacerbates Western Diet-Induced Atherogenesis and Plaque Instability
To evaluate the contribution of VSMC in AMPKα2 deletioninduced plaque instability, we generated Apoe Pravastatin, which is widely used for reducing the risk of cardiovascular disease, has been reported as an AMPKα2 activator. 37 To test whether pravastatin activates AMPK in VSMC, human aortic smooth muscle cells (HASMCs) were treated with pravastatin (0.01-50 μmol/L) for 24 hours. Consistent with a previous report in endothelial cells, 37 pravastatin caused a dose-dependent increase in AMPK phosphorylation at Thr172 in HASMC ( Figure 4G ). In addition, the Thr172 phosphorylation/activation of AMPK in mouse aorta was observed after 4 weeks of pravastatin administration ( Figure 4H ). ROS has been reported as an upstream signal for AMPK activation. 38, 39 As shown in Online Figure VIIA through VIIE, exposure of HASMC to pravastatin increased ROS and the activation of AMPK by pravastatin was effectively blocked by either Tempol or mito-Tempol, 2 potent ROS scavengers, suggesting that AMPK activation by pravastatin is ROS mediated.
Pravastatin treatment had no effect on mice body weight (Online Table I ) and total plasma cholesterol and triglyceride levels (Online Table II ). We had earlier determined whether pravastatin's protective effect on plaque stability was mediated by VSMC-derived AMPKα2. As shown in Figure 4 , pravastatin, administrated for 4 weeks, caused a 49% decrease of necrotic core size ( Figure 4C ), 17% increase of collagen ( Figure 4D and 4E), and 10% increase of fibrous cap thickness ( Figure 4F ), in Apoe
sm+/+ mice compared with to control. There was a slight decrease in plaque size after treatment with pravastatin, suggesting that pravastatin had little effect on plaque regression. As expected, unlike the effects of pravastatin in Apoe −/− AMPKα2 sm+/+ mice, pravastatin treatment had no effect on plaque stability, including plaque size, necrotic core size, collagen content, and fibrous cap thickness, in Apoe 
VSMC AMPKα2 Knockdown Eliminates the Effect of Pravastatin Treatment on VSMC Phenotypic Switching Signaling In Vivo
We further determined whether VSMC-specific AMPKα2 knockdown could induce VSMC phenotypic switching in the BA. As shown in Figure 5A through 5C, Apoe −/− AMP 
AMPKα2
sm+/+ mice fed with Western diet for 10 wk and treated with or without pravastatin for 4 wk.
Kα2
sm−/− mice exhibited significantly reduced SMA-α content in both the fibrous cap and total plaque area relative (Figure 3) . As shown in Figure 5A through 5H, pravastatin treatment not only markedly downregulated KLF4 expression in BA but also significantly increased SMA-α expression and decreased vimentin expression on the plaque cap and in the total plaque of Apoe −/− AMPKα2 sm+/+ mice. However, pravastatin treatment had no effects on the expression of SMA-α, vimentin, and KLF4 in BA in Apoe −/− AMPKα2 sm−/− mice ( Figure 5 ). In addition, the levels of SMA-α, vimentin, and KLF4 in the media of BA of these 4 group mice displayed similar trend with that in the plaque area ( Figure 5 ). Finally, we observed weak costaining of KLF4 and CD68 in BA of the mice in these 4 groups (Online Figure VIIIA) . Taken together, these results suggest that VSMC is the major cell origin of KLF4 and that pravastatin via its activation of VSMC AMPKα2 suppresses VSMC phenotypic switching.
VSMC AMPKα2 Deficiency Does Not Promote VSMC-to-Macrophage Phenotypic Switching
Shankman et al 8 demonstrate that KLF4 promotes switching of VSMC-to-macrophage phenotype in atherosclerotic plaques. Thus, we reasoned that AMPKα2 deficiency may promote VSMC-to-macrophage phenotypic switching by upregulating KLF4. To address this issue, we conducted both in vivo and in cultured VSMC experiments. We first performed immunofluorescence staining of CD68 and SMA-α in BA of Apoe 
AMPKα2
sm−/− mice (Online Figure  VIIIB) , indicating AMPKα2 activation in VSMC is required for pravastatin's effects on SMA-α.
We next examined macrophage markers in cultured VSMC under cholesterol loading. As depicted in Online Figure VIIIC , cholesterol loading caused a 2-fold increase of the mRNA levels of macrophage marker lgals3 in both wildtype (WT) and AMPKα2 −/− VSMC. In addition, under either basal-or cholesterol-treated conditions, the level of lgals3 in AMPKα2 −/− VSMC was lower than that of WT VSMC (Online Figure VIIIC) , suggesting that the loss of AMPKα2 in VSMC unlikely promotes its VSMC switching into macrophage under cultured conditions. Taken together, these results provide further evidence that AMPKα2 deficiency has no direct effect on promoting VSMC-to-macrophage phenotypic switching.
AMPKα2 Deficiency Induces VSMC Phenotypic Switching In Vitro
To elucidate the mechanism of AMPKα2 on VSMC phenotypic switching, we isolated VSMC from the aorta of WT and AMPKα2 −/− mice and detected markers of contractile and synthetic VSMC phenotypes by real-time polymerase chain reaction and Western blotting. As shown in Figure 6A , SMA-α, calponin, and SM-MHC (smooth muscle-mysion heavy chain), which are 3 canonical contractile markers of VSMC, were significantly decreased in AMPKα2 −/− VSMC compared with those from WT. In contrast, the mRNA and protein levels of vimentin and osteopontin, 2 well-characterized markers for synthetic VSMC, were dramatically increased in
AMPKα2
−/− VSMC ( Figure 6A and 6B). Consistently, transfection of AMPKα2-specific siRNA, but not of control siR-NA, in HASMC not only significantly lowered the amount of contractile proteins (SMA-α, calponin, and SM-MHC) but also caused a marked upregulation of synthetic proteins (vimentin and osteopontin; Figure 6C and 6D). Furthermore, we analyzed the levels of extracellular matrix and MMP2 protein expression and activity in WT or AMPKα2 −/− VSMC. As we expected, both collagen I and collagen IV were increased in AMPKα2 −/− VSMC compared with those from WT. Consistently, MMP2 expression and MMP2 activity were markedly elevated in AMPKα2 −/− VSMC when compared with those in WT (Online Figure IXA) . Consistently, transfection of AMPKα2-specific siRNA, but not of control siRNA, in HASMC significantly increased collagen I and MMP2 (Online Figure 9B) . Taken together, our results indicate that AMPKα2 deletion triggers the switch of contractile VSMC to the synthetic phenotypes in vitro and in vivo.
AMPKα2 Deficiency Upregulates KLF4 in VSMC
Next, we detected KLF4 protein expression in VSMC isolated from WT and AMPKα2 −/− mice. As shown in Figure 7A , KLF4 protein was significantly increased in VSMC from AMPKα2 −/− mice compared with their counterparts from WT. Furthermore, the mRNA levels of KLF4 in the VSMC from AMPKα2 −/− mice were 2.6-fold greater than those in VSMC from WT ( Figure 7B) . Similarly, siRNA knockdown of AMPKα2 in HASMC significantly increased both the mRNA level and protein expression of KLF4 ( Figure 7C and 7D) . Taken together, these results indicate that genetic inhibition of AMPKα2 in VSMC upregulated KLF4.
KLF4 Knockdown Ablates AMPKα2 Deletion-Induced VSMC Phenotypic Switches in Cultured VSMC
To further investigate a causative role of KLF4 accentuation in AMPKα2 deletion-induced VSMC phenotypic switching, the mRNA and protein expression levels of the contractile and synthetic markers were monitored in VSMC transfected with either KLF4-specific siRNA or con siRNA. As expected, transfection of KLF4-specific siRNA, but not con siRNA, significantly suppressed KLF4 expression in VSMC ( Figure 7E ).
Silencing of KLF4 in AMPKα2
−/− VSMC prevented the reduction of mRNA and protein levels for contractile markers such as SMA-α and calponin, as well as prevented upregulation of synthetic markers ( Figure 7E and 7F) .
To further confirm the involvement of KLF4 in AMPKα2 deletion-induced VSMC phenotypic switching, we concomitantly silenced both KLF4 and AMPKα2 in HASMC. As expected, siRNA-mediated KLF4 silencing rescued the attenuation of contractile markers caused by AMPKα2 deficiency ( Figure 7G and 7H) . Meanwhile, elevated expression of both protein and mRNA levels of synthetic markers mediated by AMPKα2 silence was blocked in HASMC transfected with KLF4-specific siRNA ( Figure 7G and 7H) . In summary, our results indicate that KLF4 is required for AMPKα2 deletion-induced VSMC phenotype switching in VSMC.
AMPKα2 Deficiency Upregulates KLF4 Through Nuclear Factor-κB Signaling
Next, we determined whether AMPKα2 deletion activates the nuclear factor (NF)-κB pathway in VSMC. First, we analyzed the protein expression of NF-κB pathway molecular −/− mice by using Western blots. As shown in Online Figure X , the expression of p-IκBα, pNF-κB p65, and NF-κB p65 in the nucleus were significantly increased in AMPKα2 −/− VSMC relative to VSMC from WT. In addition, AMPKα2 −/− VSMC showed decreased expression of IκBα indicating enhanced degradation of IκBα in VSMC. These data suggest that AMPKα2 deficiency in VSMC resulted in overactivation of NF-κB and consequent KLF4 upregulation. To further study the contributions of the NF-κB pathway in AMPKα2 deletion-mediated KLF4 upregulation, we used a synthetic NF-κB inhibitor that inhibits translocation of the NF-κB active complex into the nucleus, thereby pharmacologically blocking the NF-κB pathway in WT and AMPKα2 −/− VSMC. Notably, the inhibition of NF-κB abolished AMPKα2 deficiency-induced upregulation of KLF4 protein and mRNA levels ( Figure 8A and 8B) . NF-κB p65 and AMPKα2 were concomitantly silenced in HASMC. As depicted in Figure 8C and 8D, silencing of NF-κB p65 ablated KLF4 upregulation in AMPKα2-silenced HASMC, suggesting that the NF-κB pathway plays a critical role in AMPKα2 deficiency-mediated KLF4 upregulation.
Considering that AMPKα2 deficiency upregulates both the mRNA level and protein expression of KLF4, we hypothesized that AMPKα2 deficiency may upregulate KLF4 through transcriptional activation. By using the Transcription Factor Database (http://www.gene-regulation.com), we found that KLF4's upstream promoter contains a putative NF-κB p65-binding site (tcccagggaagtccct; at 2018 bp). To confirm the predicted site of the KLF4 promoter is required for increased KLF4 expression in HASMC in response to AMPKα2 deficiency, we constructed 2 promoter-reporter plasmids containing different lengths of KLF4 promoter ( Figure 8E ). HASMC were transfected with different KLF4 promoter-reporter plasmids along with con siRNA and AMPKα2 siRNA. Promoter activity was analyzed by luciferase assay. As depicted in Figure 8F , AMPKα2 deficiency increased the activity of the 2600-bp promoter, however, had no effect on the activity of the 1583-bp promoter, implying that the regulatory element necessary for AMPKα2 deficiency-induced increase in KLF4 expression is located between 1583 and 2600 bp, which is consistent with our prediction.
To directly test whether the 2018 bp predicted site within the KLF4 promoter was responsible for transcriptional regulation by AMPKα2 /NF-κB pathway, we performed a promoter assay (luciferase reporter assay) using a KLF4 promoter containing a mutation at 2018 bp. HASMC were simultaneously transfected with WT or KLF4 mutant 2018 bp promoter-reporter plasmid along with con siRNA and AMPKα2 siRNA. Mutagenesis analysis of KLF4 promoter showed that deletion of the region that contains the potential NF-κB site (2018 bp) blocked the increase of the promoter activity induced by AMPKα2 deficiency compared with WT plasmid in HASMC. A significant reduction of KLF4 promoter activity in 1583-bp construct compared with 2600 bp was also observed in HASMC ( Figure 8G ).
Finally, we determined the effect of AMPKα2 deficiency on binding activity of NF-κB p65 with the KLF4 promoter. Different primers were designed, and DNA chromatin immunoprecipitation assays were performed in AMPKα2 −/− and WT VSMC. As expected, AMPKα2 deletion markedly promoted the binding of NF-κB p65 to the KLF4 promoter ( Figure 8H ). Taken together, AMPKα2 deletion via NF-κB transcriptional regulation induced KLF4 upregulation.
Discussion
The current study demonstrates for the first time that AMPKα2 plays a novel role as a powerful negative regulator of VSMC phenotypic switching. Genetic inactivation of AMPKα2 downregulated contractile proteins while upregulating synthetic proteins in the atherosclerotic plaques and in isolated VSMC. Mechanistically, this phenotype is attributable to NF-κB activation-induced transcriptional upregulation of KLF4 in VSMC. Consistently, genetic or pharmacological inhibition of either KLF4 or NF-κB ablated VSMC phenotypic switching in cultured VSMC. Furthermore, our study suggests that AMPKα2 deletion promotes the features of atherosclerotic plaque instability. VSMC-specific AMPKα2 −/− mice exhibited aggravated VSMC phenotypic switching and obvious features of plaque instability. Importantly, pravastatin treatment significantly suppressed VSMC phenotypic switching and enhanced plaque stability in Apoe −/− AMPK α2sm +/+ control mice but had no effect in VSMC-specific AMPKα2 −/− mice. These results imply that AMPKα2 plays a protective role in regulating VSMC phenotypic switching and plaque stability.
The major finding of this study is that AMPKα2 deletion in VSMC enhances atherosclerotic plaque instability. Accumulating evidence indicate that AMPK acts as an important regulator in the pathogenesis of cardiovascular diseases. 40 In our present study, we found that genetic inactivation of AMPKα2 promotes features of unstable plaques in advanced Western diet-induced atherosclerotic lesions within the BA. We further confirmed our findings using VSMC-specific AMPKα2 −/− mice, which displayed similar features of plaque instability in the BA to that of global AMPKα2 −/− mice. Those data indicate that VSMC-derived AMPKα2, even as a minor isoform, does play an important protective role in plaque stabilization.
Another major finding of this study is we demonstrate that AMPKα2 deletion promotes VSMC phenotypic switching in a NF-κB-KLF4-dependent manner. KLF4 has been reported to function as a critical regulator in atherosclerosis. 8, 41 However, the regulation of KLF4 is still not fully understood. Accumulated evidence suggests that KLF4 can be transcriptionally induced in macrophages, VSMC, and other cell types of the vessel in response to vascular injury. 42, 43 In addition, KLF4 activity may also be regulated by post-translational modifications including acetylation, phosphorylation, and sumoylation. [44] [45] [46] Here, in the present study, we demonstrate that AMPKα2 deficiency activates the NF-κB pathway in VSMC, which is consistent with our previous studies in endothelial cells. 18 Importantly, we report for the first time that NF-κB p65 binds with KLF4 promoter and transcriptionally regulates its expression, which provide a novel mechanism for KLF4 regulation in VSMC. Evidence demonstrates that many transcriptional regulatory pathways, including but not limited to serum response factor, myocardin, KLF4, and FoxO4 control VSMC switching from −/− VSMC treated with NF-κB control. C, Western blot analysis of KLF4 expression in human aortic smooth muscle cells (HASMCs) treated with NF-κBp65 siRNA and AMPKα2 siRNA (n=5). *, P<0.05 vs con siRNA. #P<0.05 vs AMPKα2 siRNA. D, Quantitative real-time PCR analysis of mRNA level of KLF4 in HASMC treated with NF-κBp65 siRNA and AMPKα2 siRNA (n=5). *P<0.05 vs con siRNA. #P<0.05 vs AMPKα2 siRNA. E, The KLF4 promoter was analyzed using the Transcription Factor Database software, suggesting one binding site within the promoter. 2600 bp and 1583 bp KLF4 promoter luciferase constructs are shown. F, HASMC were transfected with 2600-and 1583-bp KLF4 promoter luciferase constructs and treated with con siRNA or AMPKα2 siRNA, and luciferase activity was measured after 24 h. Results of the luciferase reporter assay are presented as fold changes±SEM of the Firefly/Renilla luciferase activities (n=5). *P<0.05 vs HASMC transfected with 2600-bp KLF4 promoter luciferase construct and con siRNA. #P<0.05 vs HASMC transfected with 2600-bp KLF4 promoter luciferase construct and AMPKα2 siRNA. G, HASMC were transfected with either WT or the mutant KLF4 promoter-reporter and treated with con siRNA or AMPKα2 siRNA for 24 h to detect the luciferase activity (n=5). *P<0.05 vs HASMC transfected with WT 2600-bp KLF4 promoter reporter and con siRNA. #P<0.05 vs HASMC transfected with WT 2600-bp KLF4 promoter reporter and AMPKα2 siRNA. H, Chromatin immunoprecipitation assay for NF-κBp65 binding with KLF4 promoter in WT and AMPKα2 −/− mouse VSMC. September 2, 2016 a contractile to synthetic phenotype. 47, 48 In our study, we found that AMPKα2 deficiency enhanced VSMC phenotypic switching via upregulating KLF4.
Our results provide a novel role of AMPKα2 as a strong negative regulator in VSMC phenotypic switching. Consistent with the strong secretion character of synthetic VSMC, we observed significantly increased extracellular matrix such as collagen I and collagen IV in AMPKα2 −/− VSMC compared with those in WT. Meanwhile, MMP2 expression and MMP2 activity were also markedly elevated in AMPKα2 −/− VSMC when compared with those in WT (Online Figure IXA) . Because MMPs can degrade collagen, the levels of collagen in vascular tissues are determined by the rates of its de novo synthesis and MMP2 degradation. The MMPs-mediated collagen degradation seems to output de novo collagen synthesis in AMPKα2 −/− VSMC, as the levels of collagen contents in the atherosclerotic plaque of Ap oe −/− AMPKα2 −/− mice are lower than those in Apoe −/− mice ( Figure 1I and 1J ). VSMC deletion of AMPKα2 promotes KLF-mediated VSMC phenotypic switching resulting in decrease of collagen and reduced plaque stability. Overall, our study supports the notion that selective AMPKα2 activation in VSMC might be an effective therapy for treating unstable coronary heart diseases.
Accumulating studies have reported that statins can reduce the risk of acute coronary syndrome caused by plaque rupture 6 ; however, the mechanism is still unclear. It has been reported that pravastatin could increase plaque stability and inhibit thrombosis through both lipid-dependent and lipidindependent way. Recently, increasing evidence demonstrates that statins have potent anti-inflammation effects that contribute to atherosclerotic plaque stabilization. 49 In our study, 50-mg/kg per day pravastatin was used for the treatment of plaque instability. This dose was chosen according to the guideline of pravastatin sodium tablets, in which illustrates that 100-mg/kg per day dose produces drug exposures ≈2× the human dose of 80 mg based on area under the curve. In addition, several groups have verified that 50-mg/ kg per day pravastatin is an appropriate dose for preventing cardiovascular disease and renal ischemia reperfusion injury in mouse model. 50, 51 We found that 4-week treatment with pravastatin alleviates Western diet-induced plaque instability in advanced atherosclerosis, which is consistent with previous studies reporting the beneficial effect of statins on plaque stability. 27, 32, 52, 53 Interestingly, pravastatin has no effect on serum cholesterol and triglyceride levels, which demonstrate that the protective effect of pravastatin on plaque stability in our study is lipid independent. Consistent with early reports that statin activated AMPK in mice endothelial cells, 37 we found that pravastatin efficiently activated AMPK in VSMC and in aorta from Western diet-treated mice ( Figure 4A and 4B) . However, AMPK activation in endothelial cells reported by us 37 and others 54 seems to be unrelated to statin's protective effects in plaque stability because the effect of pravastatin on plaque stability was abolished in VSMC-specific AMPKα2 −/− mice. These data indicate that pravastatin enhances plaque stability via directly activating VSMC-derived AMPKα2. These findings suggest that AMPKα2, especially VSMC-derived AMPKα2, is an attractive therapeutic target for enhancing atherosclerotic plaque stability in clinical practice. As would be expected, AMPKα2 agonist, especially VSMC-specific AMPKα2 agonist, may have direct beneficial effect on prevention of atherosclerotic plaque instability. This finding holds promise in leading to effective preventive and therapeutic strategies for vascular diseases.
Because rupture of the atherosclerotic plaque is hard to study directly in humans, it is important to use mouse model to understand how rupture occurs and explore novel therapeutic measures to prevent it from happening. The BA has been reported as the only site in high-fat diet-fed mouse that could display multiple features of plaque instability. 32 However, this model only partially mimics the features of unstable plaque in humans, likely because of its lack of thrombosis formation in mice. 23 In addition, the BA is very small and consequently difficult to process for histology. Until now, there has been no ideal mouse model of human plaque rupture; hence, we focused on BA for studying plaque vulnerability in terms of an advanced atherosclerotic lesion as a useful mouse model.
In conclusion, results of the present study provide evidence that AMPKα2 plays a protective role in suppressing VSMC phenotypic switching and enhancing plaque stability in advanced atherosclerosis. This novel finding provides rationale for AMPKα2 as a potential therapeutic target in preventing atherosclerotic plaque instability.
